Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index; none of the 37 sources its claims cite is checked for support yet.

Raf Kinase Inhibitory Protein regulates the cAMP-dependent protein kinase signaling pathway through a positive feedback loop

Open access

Abstract

Raf Kinase Inhibitory Protein (RKIP) maintains cellular robustness and prevents the progression of diseases such as cancer and heart disease by regulating key kinase cascades including MAP kinase and protein kinase A (PKA). Phosphorylation of RKIP at S153 by Protein Kinase C (PKC) triggers a switch from inhibition of Raf to inhibition of the G protein coupled receptor kinase 2 (GRK2), enhancing signaling by the β-adrenergic receptor (β-AR) that activates PKA. Here we report that PKA-phosphorylated RKIP promotes β-AR–activated PKA signaling. Using biochemical, genetic, and biophysical approaches, we show that PKA phosphorylates RKIP at S51, increasing S153 phosphorylation by PKC and thereby triggering feedback activation of PKA. The S51V mutation blocks the ability of RKIP to activate PKA in prostate cancer cells and to induce contraction in primary cardiac myocytes in response to the β-AR activator isoproterenol, illustrating the functional importance of this positive feedback circuit. As previously shown for other kinases, phosphorylation of RKIP at S51 by PKA is enhanced upon RKIP destabilization by the P74L mutation. These results suggest that PKA phosphorylation at S51 may lead to allosteric changes associated with a higher-energy RKIP state that potentiates phosphorylation of RKIP at other key sites. This allosteric regulatory mechanism may have therapeutic potential for regulating PKA signaling in disease states.

Overview

CoChat Summary

TL;DR

The paper identifies a positive feedback loop in which PKA-C phosphorylates RKIP at S51, enhancing PKC phosphorylation of RKIP at S153, inhibiting GRK2, up-regulating β-adrenergic receptor signaling, increasing cAMP, and further activating PKA. This loop potentiates PKA activity in prostate cancer cells and cardiac myocytes, and the authors propose S51 as a diagnostic marker and therapeutic target.

Key findings

  • PKA-C phosphorylates RKIP primarily at S51 in vitro; S51V abolished detectable phosphorylation, S52V enhanced it, and S52E suppressed it. Table 1 reports WT Vmax 1,726 ± 126 pmol min−1 mg−1 and Km 38 ± 7 μM; S52V Vmax 9,852 ± 599 and Km 55 ± 7 μM; P74L Vmax 3,620 ± 163 and Km 17 ± 2 μM; G57K Vmax 1,020 ± 32 and Km 33 ± 3 μM.
  • In PC-3 prostate cancer cells, isoproterenol increased S51 phosphorylation about twofold; anti-pS51 recognized RKIPWT but not S51V. S51 phosphorylation enhanced PKC phosphorylation at S153: S51V decreased pS153 after TPA, while S51E was phosphorylated at S153 with or without TPA. cAMP increased with RKIPWT plus isoproterenol and further with TPA, whereas S51V prevented optimal cAMP stimulation. PKA activity (pVASP) was potentiated by WT, blocked by S51V, and increased by S51E with isoproterenol without added TPA; H89 suppressed VASP phosphorylation.
  • In cardiac myocytes, S51V reduced PKC phosphorylation at S153 and suppressed the isoproterenol response; S51V also reduced contractile activity to control levels upon isoproterenol relative to RKIPWT (WT + PMA vs. V51 + PMA: P = 0.0178; WT + ISO vs. V51 + ISO: P = 0.0016; contractility from 20 replicates of five independent experiments, *P < 0.01 vs. Con-Iso and #P < 0.0001 as indicated).
  • BLI showed RKIPWT binds apo PKA-C with Kd ≈ 36 μM and ATPγN-saturated PKA-C with Kd ≈ 6 μM, a sixfold enhancement (Table 2: 36.4 ± 0.7 μM vs. 6.2 ± 0.7 μM; cooperativity σ = 6). NMR chemical shift perturbations mapped RKIP residues near S51 and one face of RKIP, with long-range effects at Q183 and L180; P74L showed a similar CSP profile, and G57K reduced Vmax by almost 50%. PKA-C interface changes involved the Gly-rich, catalytic, DFG, and activation loops, similar to PKI but attenuated.

Methods

  • In vitro kinase assays used recombinant PKA-C and rat RKIP mutants, with site-directed mutagenesis, phospho-imaging, and immunoblotting; a pS51-specific antibody was generated and purified against a phosphopeptide.
  • Cell experiments used PC-3 prostate cancer cells depleted of endogenous RKIP by shRNA and reconstituted with vector, RKIPWT, RKIPS51V, or RKIPS51E, then treated with isoproterenol, TPA, H89, or BIS; readouts included pS51, pS153, cAMP ELISA, and pVASP PKA activity. Cardiac myocytes were adenovirally transduced with WT or S51V RKIP, and contractility was measured.
  • Biophysical characterization used biolayer interferometry with apo and ATPγN-saturated PKA-C and NMR HSQC/TROSY titrations with 15N-labeled RKIP and PKA-C to map binding interfaces.

Limitations

  • Stated in the paper: more in-depth analyses are required to elucidate the detailed molecular mechanism by which S51 phosphorylation potentiates S153 phosphorylation; the interaction studies do not fully explain this. The authors also state that whether RKIP generates discrete PKA outputs or fine-tunes homeostatic control requires further analysis, and that ATPγN’s lower affinity/cooperativity may explain discrepancies between in vitro binding studies and in-cell assays.
  • Evident from the text: mechanistic work relies on recombinant proteins, PC-3 cells, and cardiac myocytes rather than in vivo disease models or human tissue validation. The S51E phosphomimetic is an approximation of phosphorylation, and the paper does not provide a structure of S51-phosphorylated RKIP or direct PKC-binding measurements.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1073/pnas.2121867119

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1. Phosphorylation of RKIP by PKA. (A and B) Purified RKIP proteins were tested for in vitro kinase assays. After immunoblotting with anti-RKIP antibody, the phosphorylation levels were quantified using ImageQuant 5.2 software and normalized to RKIP protein levels to compare the phosphorylation between the various mutants. The fold induction shown in the bar graphs is an average of three experiments, and the error bars indicate SEM. (C) Immunoblotting purified WT (PKA-) and PKA-phosphorylated RKIP (PKA+) with unfractionated anti-pS51 antiserum (Sera) and purified antibody (Eluate). Rabbit serum was purified on an anti–phospho-S51 RKIP peptide column as described in Materials and Methods. (D) Immunoblotting of lysates from PC-3 prostate cancer cells treated with isoproterenol (Iso). PC-3 cells that had been stably depleted of RKIP by expression of human RKIP shRNA were transfected with a control vector (VC), RKIPWT, or the S51V RKIP mutant. Cells were lysed, and lysates were immunoblotted with anti-pS51 RKIP antibody or anti-tubulin antibody. For isoproterenol treatment, cells were serum-starved for 20 h and then either treated with DMSO or stimulated with 0.005, 0.05, or 1 μM isoproterenol (Iso) for 10 min. Cells were lysed, and lysates were immunoblotted with anti-pS51 RKIP antibody or anti-tubulin antibody. The protein bands were quantified using Licor ImageStudio, and the results were plotted for pS51 phosphorylation relative to tubulin. Mean values from four independent experiments were plotted, and P values were obtained using a Student’s t test. *P < 0.05.
Fig. 1. Phosphorylation of RKIP by PKA. (A and B) Purified RKIP proteins were tested for in vitro kinase assays. After immunoblotting with anti-RKIP antibody, the phosphorylation levels were quantified using ImageQuant 5.2 software and normalized to RKIP protein levels to compare the phosphorylation between the various mutants. The fold induction shown in the bar graphs is an average of three experiments, and the error bars indicate SEM. (C) Immunoblotting purified WT (PKA-) and PKA-phosphorylated RKIP (PKA+) with unfractionated anti-pS51 antiserum (Sera) and purified antibody (Eluate). Rabbit serum was purified on an anti–phospho-S51 RKIP peptide column as described in Materials and Methods. (D) Immunoblotting of lysates from PC-3 prostate cancer cells treated with isoproterenol (Iso). PC-3 cells that had been stably depleted of RKIP by expression of human RKIP shRNA were transfected with a control vector (VC), RKIPWT, or the S51V RKIP mutant. Cells were lysed, and lysates were immunoblotted with anti-pS51 RKIP antibody or anti-tubulin antibody. For isoproterenol treatment, cells were serum-starved for 20 h and then either treated with DMSO or stimulated with 0.005, 0.05, or 1 μM isoproterenol (Iso) for 10 min. Cells were lysed, and lysates were immunoblotted with anti-pS51 RKIP antibody or anti-tubulin antibody. The protein bands were quantified using Licor ImageStudio, and the results were plotted for pS51 phosphorylation relative to tubulin. Mean values from four independent experiments were plotted, and P values were obtained using a Student’s t test. *P < 0.05.CC BY-NC-ND · PubMed Central
Fig. 2. PKA phosphorylates RKIP at Serine 51, increasing both PKC phosphorylation of RKIP at Serine 153 and PKA activity in prostate tumor cells. For A–E, PC-3 cells stably expressing RKIP shRNA were transfected with control vector (VC), WT, or mutant RKIP (S51V, S51E) and serum-starved for 20 h before stimulation using TPA for 30 min, isoproterenol (Iso) for 10 min, or H89 for 30 min as indicated. (A) Phosphorylation of RKIP and mutant S51V RKIP at S153 in PC3 cells after TPA treatment. Cell lysates were immunoblotted with anti-pS153 RKIP antibody or anti-Actin antibody and quantified for plots. The lower band on phosphorylated RKIP and RKIP blots is nonspecific. (B) Phosphorylation of RKIP and mutant RKIP S51E at S513 after TPA and Iso treatment in PC3 cells. Cell lysates were immunoblotted with anti-pS153 RKIP antibody, anti-RKIP antibody, or anti-tubulin antibody. (C) Phosphorylation of S51 RKIP enhances cAMP levels in prostate tumor cells. Total cAMP levels were quantified as in Materials and Methods. (D) Phosphorylation of S51 RKIP enhances PKA activity in prostate tumor cells. Cell lysates were assayed for PKA activity by immunoblotting with anti-pVASP antibody. Samples were normalized to tubulin by immunoblotting with anti-tubulin antibody. (E) An S51V mutant reduces activation of PKA in TPA/Iso-stimulated cells, and S51E potentiates activation of PKA. Cell lysates were assayed for PKA activity by immunoblotting with anti-pVASP antibody. Samples were normalized to tubulin by immunoblotting with anti-tubulin antibody. Samples were quantified using Licor ImageStudio. Mean values from three independent experiments were plotted, and P values were obtained using a Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Fig. 2. PKA phosphorylates RKIP at Serine 51, increasing both PKC phosphorylation of RKIP at Serine 153 and PKA activity in prostate tumor cells. For A–E, PC-3 cells stably expressing RKIP shRNA were transfected with control vector (VC), WT, or mutant RKIP (S51V, S51E) and serum-starved for 20 h before stimulation using TPA for 30 min, isoproterenol (Iso) for 10 min, or H89 for 30 min as indicated. (A) Phosphorylation of RKIP and mutant S51V RKIP at S153 in PC3 cells after TPA treatment. Cell lysates were immunoblotted with anti-pS153 RKIP antibody or anti-Actin antibody and quantified for plots. The lower band on phosphorylated RKIP and RKIP blots is nonspecific. (B) Phosphorylation of RKIP and mutant RKIP S51E at S513 after TPA and Iso treatment in PC3 cells. Cell lysates were immunoblotted with anti-pS153 RKIP antibody, anti-RKIP antibody, or anti-tubulin antibody. (C) Phosphorylation of S51 RKIP enhances cAMP levels in prostate tumor cells. Total cAMP levels were quantified as in Materials and Methods. (D) Phosphorylation of S51 RKIP enhances PKA activity in prostate tumor cells. Cell lysates were assayed for PKA activity by immunoblotting with anti-pVASP antibody. Samples were normalized to tubulin by immunoblotting with anti-tubulin antibody. (E) An S51V mutant reduces activation of PKA in TPA/Iso-stimulated cells, and S51E potentiates activation of PKA. Cell lysates were assayed for PKA activity by immunoblotting with anti-pVASP antibody. Samples were normalized to tubulin by immunoblotting with anti-tubulin antibody. Samples were quantified using Licor ImageStudio. Mean values from three independent experiments were plotted, and P values were obtained using a Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.CC BY-NC-ND · PubMed Central
Fig. 3. Positive feedback loop between RKIP and PKA leads to enhanced contractility in cardiac myocytes. (A) Cardiac myocytes were adenovirally transduced with WT or S51V RKIP, and treated with or without TPA (PMA). Cell lysates were immunoblotted for RKIP or pS153 RKIP. (B) Cardiac myocytes were adenovirally transduced with WT or S51V RKIP and then treated with or without isoproterenol. Cell lysates were immunoblotted for RKIP or pS153 RKIP. (C) Cardiac myocytes were adenovirally transduced and treated with isoproterenol as in B. For the control (Con), LacZ was adenovirally transduced. Contractility was measured as described in Materials and Methods. Mean values from five (A) or six (B) independent experiments were plotted, and P values were obtained using a one-way ANOVA and Sidak’s post hoc test (WT + PMA vs. V51 + PMA: P = 0.0178 and WT + ISO vs. V51 + ISO: P = 0.0016). (C) Mean values from 20 replicates of five independent experiments were plotted, and P values were obtained using a one-way ANOVA and Tukey’s post hoc test (*P < 0.01 vs. Con-Iso and #P < 0.0001 as indicated). (D) Scheme depicting positive feedback loop between RKIP and PKA. RKIP phosphorylated at S153 by PKC inhibits GRK2, reducing down-regulation of the β-adrenergic receptor (β-AR). β-AR activates PKA, which then phosphorylates RKIP at S51 leading to enhanced phosphorylation by PKC at S153.
Fig. 3. Positive feedback loop between RKIP and PKA leads to enhanced contractility in cardiac myocytes. (A) Cardiac myocytes were adenovirally transduced with WT or S51V RKIP, and treated with or without TPA (PMA). Cell lysates were immunoblotted for RKIP or pS153 RKIP. (B) Cardiac myocytes were adenovirally transduced with WT or S51V RKIP and then treated with or without isoproterenol. Cell lysates were immunoblotted for RKIP or pS153 RKIP. (C) Cardiac myocytes were adenovirally transduced and treated with isoproterenol as in B. For the control (Con), LacZ was adenovirally transduced. Contractility was measured as described in Materials and Methods. Mean values from five (A) or six (B) independent experiments were plotted, and P values were obtained using a one-way ANOVA and Sidak’s post hoc test (WT + PMA vs. V51 + PMA: P = 0.0178 and WT + ISO vs. V51 + ISO: P = 0.0016). (C) Mean values from 20 replicates of five independent experiments were plotted, and P values were obtained using a one-way ANOVA and Tukey’s post hoc test (*P < 0.01 vs. Con-Iso and #P < 0.0001 as indicated). (D) Scheme depicting positive feedback loop between RKIP and PKA. RKIP phosphorylated at S153 by PKC inhibits GRK2, reducing down-regulation of the β-adrenergic receptor (β-AR). β-AR activates PKA, which then phosphorylates RKIP at S51 leading to enhanced phosphorylation by PKC at S153.CC BY-NC-ND · PubMed Central
Fig. 4. NMR map of the residues of RKIPWT and P74L mutant involved in PKA-C/RKIP interaction interface. (A and B) [1H,15N]-HSQC spectra showing the backbone chemical shift changes of selected resonances of (A) RKIPWT and (B) RKIPP74L upon titration of increasing amount of PKA-C/ATPγN complex. (C) CSP of the amide fingerprint of RKIPWT and RKIPP74L mutant alone (Δδfree) and in a 1:2 complex with PKA-C/ATPγN (Δδbound) vs. residues, calculated using Eq. 1. The residues that show a CSP value two times greater than 1 SD from the average CSP (gray dashed line) are indicated in the histogram. (D–G) Cartoon (D) and surface (E) mapping of the amide CSP of RKIPWT or cartoon (F) and surface (G) of P74L mutant onto the three-dimensional structure (Protein Data Bank [PDB] ID 2IQY). The cartoons and the surfaces are colored according the CSP values ranging from 0.015 to 0.15 ppm.
Fig. 4. NMR map of the residues of RKIPWT and P74L mutant involved in PKA-C/RKIP interaction interface. (A and B) [1H,15N]-HSQC spectra showing the backbone chemical shift changes of selected resonances of (A) RKIPWT and (B) RKIPP74L upon titration of increasing amount of PKA-C/ATPγN complex. (C) CSP of the amide fingerprint of RKIPWT and RKIPP74L mutant alone (Δδfree) and in a 1:2 complex with PKA-C/ATPγN (Δδbound) vs. residues, calculated using Eq. 1. The residues that show a CSP value two times greater than 1 SD from the average CSP (gray dashed line) are indicated in the histogram. (D–G) Cartoon (D) and surface (E) mapping of the amide CSP of RKIPWT or cartoon (F) and surface (G) of P74L mutant onto the three-dimensional structure (Protein Data Bank [PDB] ID 2IQY). The cartoons and the surfaces are colored according the CSP values ranging from 0.015 to 0.15 ppm.CC BY-NC-ND · PubMed Central
Fig. 5. NMR mapping of the PKA-C residues involved in the PKA-C/RKIP interactions. (A) CSPs of the PKA-C/ATPγN fingerprint upon interaction with RKIPWT (black) and PKI. The shaded colors indicate the Gly-rich loop (green), catalytic loop (yellow), DFG loop (orange), activation loop (purple), P + 1 loop (blue), and APE (red). (B) Chemical shift changes mapped onto the PKA-C structure (PDB ID 4wb5). The hot pink spheres highlight residues that broaden out, while the orange spheres indicate those residues that sharpened out upon interacting with RKIPWT. (C) [1H,15N]-TROSY-HSQC spectra overlay for specific residues of PKA-C in complex with ATPγN (orange), ATPγN/RKIP (purple), and ATPγN/PKI (green).
Fig. 5. NMR mapping of the PKA-C residues involved in the PKA-C/RKIP interactions. (A) CSPs of the PKA-C/ATPγN fingerprint upon interaction with RKIPWT (black) and PKI. The shaded colors indicate the Gly-rich loop (green), catalytic loop (yellow), DFG loop (orange), activation loop (purple), P + 1 loop (blue), and APE (red). (B) Chemical shift changes mapped onto the PKA-C structure (PDB ID 4wb5). The hot pink spheres highlight residues that broaden out, while the orange spheres indicate those residues that sharpened out upon interacting with RKIPWT. (C) [1H,15N]-TROSY-HSQC spectra overlay for specific residues of PKA-C in complex with ATPγN (orange), ATPγN/RKIP (purple), and ATPγN/PKI (green).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 20 Not checked · 72 Own results and interpretations

54 more claims

Create a free account to see all 92 claims and to verify the 37 references still open.

See all claims — free account
  • It may state two separate claims as one. 18
  • Probably not a substantial claim. 18
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 42 references

Research works printed but not linked: 1

  1. D. Goddard, D. G. Kneller, Sparky 3 (University of California, San Francisco, 2004).

Cited by

See all 20

Metadata

Authors
Lee, J., Olivieri, C., Ong, C., Masterson, L. R., Gomes, S., Lee, B.-S., Schaefer, F., Lorenz, K., Veglia, G., & Rosner, M. R.
Affiliations
  • University of Chicago (US)
  • University of Minnesota (US)
  • George Washington University (US)
  • University of Würzburg (DE)
Corresponding author
  • Veglia, Gianluigi
  • Rosner, Marsha Rich
Venue
Proceedings of the National Academy of Sciences
Published
2022-06-13
Volume
119
Issue
25
Pages
e2121867119-e2121867119
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W4282582314
Cited by
20
References
42
Citations by year
2026: 5 · 2025: 7 · 2024: 2 · 2023: 3 · 2022: 3
FWCI
1.04
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Knowledge@UChicago (University of Chicago) (submittedVersion, cc-by-nc-nd)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • University of Chicago (cc-by-nc-nd)
Funders
  • HHS | NIH | National Institute of General Medical Sciences (GM087630, GM121735, GM100310)
  • Deutsche Forschungsgemeinschaft (SFB1116/A09, SFB/TR296/P10)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Phosphodiesterase function and regulation
Keywords
RKIP, protein kinase A, positive feedback loop, protein kinase A phosphorylation, protein kinase C, allosteric regulation, beta-adrenergic signaling, G protein-coupled receptor kinase 2, prostate cancer, cardiac myocyte contraction, isoproterenol
MeSH terms
PC-3 Cells, Humans, Male, Phosphorylation, Prostatic Neoplasms, Protein Kinase C, Signal Transduction, Cyclic AMP-Dependent Protein Kinases, Feedback, Physiological, Phosphatidylethanolamine Binding Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Raf Kinase Inhibitory Protein regulates the cAMP-dependent protein kinase signaling pathway through a positive feedback loop. https://app.cochat.ai/papers/10.1073/pnas.2121867119
The paper
Lee, J., Olivieri, C., Ong, C., Masterson, L. R., Gomes, S., Lee, B.-S., Schaefer, F., Lorenz, K., Veglia, G., & Rosner, M. R. (2022). Raf Kinase Inhibitory Protein regulates the cAMP-dependent protein kinase signaling pathway through a positive feedback loop. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2121867119

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.